GlycoMimetics Research and Development Expenses 2012-2025 | CBIO
GlycoMimetics research and development expenses from 2012 to 2025. Research and development expenses can be defined as an expense arising from studies and product development processes.
GlycoMimetics Annual Research and Development Expenses
(Millions of US $) |
| 2024 |
$14 |
| 2023 |
$20 |
| 2022 |
$28 |
| 2021 |
$47 |
| 2020 |
$45 |
| 2019 |
$47 |
| 2018 |
$40 |
| 2017 |
$24 |
| 2016 |
$23 |
| 2015 |
$25 |
| 2014 |
$20 |
| 2013 |
$12 |
| 2012 |
$9 |
| 2011 |
$8 |
GlycoMimetics Quarterly Research and Development Expenses
(Millions of US $) |
| 2025-03-31 |
$0 |
| 2024-12-31 |
$0 |
| 2024-09-30 |
$2 |
| 2024-06-30 |
$6 |
| 2024-03-31 |
$6 |
| 2023-12-31 |
$5 |
| 2023-09-30 |
$5 |
| 2023-06-30 |
$4 |
| 2023-03-31 |
$5 |
| 2022-12-31 |
$6 |
| 2022-09-30 |
$5 |
| 2022-06-30 |
$8 |
| 2022-03-31 |
$10 |
| 2021-12-31 |
$13 |
| 2021-09-30 |
$13 |
| 2021-06-30 |
$10 |
| 2021-03-31 |
$11 |
| 2020-12-31 |
$12 |
| 2020-09-30 |
$11 |
| 2020-06-30 |
$10 |
| 2020-03-31 |
$13 |
| 2019-12-31 |
$11 |
| 2019-09-30 |
$11 |
| 2019-06-30 |
$13 |
| 2019-03-31 |
$12 |
| 2018-12-31 |
$12 |
| 2018-09-30 |
$10 |
| 2018-06-30 |
$9 |
| 2018-03-31 |
$9 |
| 2017-12-31 |
$7 |
| 2017-09-30 |
$6 |
| 2017-06-30 |
$6 |
| 2017-03-31 |
$6 |
| 2016-12-31 |
$6 |
| 2016-09-30 |
$6 |
| 2016-06-30 |
$6 |
| 2016-03-31 |
$6 |
| 2015-12-31 |
$7 |
| 2015-09-30 |
$5 |
| 2015-06-30 |
$8 |
| 2015-03-31 |
$5 |
| 2014-12-31 |
$5 |
| 2014-09-30 |
$5 |
| 2014-06-30 |
$5 |
| 2014-03-31 |
$4 |
| 2013-12-31 |
$3 |
| 2013-09-30 |
$3 |
| 2013-06-30 |
$3 |
| 2013-03-31 |
$3 |
| 2012-12-31 |
|
| 2012-09-30 |
$0 |
| 2011-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.009B |
$0.000B |
|
GlycoMimetics, Inc. is a biotechnology company. The company focused on the discovery and development of novel glycomimetic drugs to address diseases in which carbohydrate biology plays a key role. It product pipeline includes GMI-170, GMI-1271, E-selectin and CXCR4 antagonist, GMI-1051 and GMI-1070 at different clinical phases. GlycoMimetics, Inc. is based in Gaithersburg, United States.
|
